Strategic partnerships Collaborate with leading cancer and GI disease centers (e.g., Gustave Roussy) to co-develop or run investigator-initiated trials leveraging NM-136 and other pipeline assets, expanding clinical evidence and access to patient populations.

Clinical advancement Highlight NM-136 and GIP antagonist programs as near-term clinical development opportunities for obesity and metabolic disorders, targeting pharmaceutical partners seeking obesity-related assets with IND-enabling pathways.

Financial feasibility Position the company’s funding runway and debt facilities as a leverage point for potential co-development or milestone-based collaborations, appealing to partners seeking project financing alongside scientific risk-sharing.

Early-stage engagement Engage through pre-IND and FDA interactions as an entry point for collaboration with CROs, contract manufacturers, and regulatory consultancies to streamline development timelines for potential partners.

Market and patient access Leverage clinical-stage focus on rare and debilitating GI diseases to identify niche payer and patient-advocacy partnerships, enabling access programs and real-world data generation to support value-based pricing discussions.